Active substance
Results for the substance samarium lexidronam pentasodium
1 result
About this active substance
Samarium lexidronam pentasodium is a radiopharmaceutical used in the treatment of bone pain associated with osteoblastic bone metastases. It contains samarium-153, a radioactive isotope that emits beta and gamma radiation, and a phosphonate ligand that selectively binds to areas of increased osteoblastic activity.
Samarium lexidronam is administered intravenously, usually as a single dose, and is used to relieve pain in patients with bone metastases caused by cancers such as prostate or breast cancer. The radiation emitted by samarium-153 destroys tumor cells in the bone, reducing pain and improving quality of life.
Common side effects include decreased blood cell counts (myelosuppression), nausea, and fatigue. In rare cases, allergic reactions or radiation-related complications may occur. Regular monitoring of blood counts is essential to prevent hematologic complications.
Samarium lexidronam pentasodium is an effective therapeutic option for managing bone pain in patients with metastases, providing significant symptom relief.
Samarium lexidronam is administered intravenously, usually as a single dose, and is used to relieve pain in patients with bone metastases caused by cancers such as prostate or breast cancer. The radiation emitted by samarium-153 destroys tumor cells in the bone, reducing pain and improving quality of life.
Common side effects include decreased blood cell counts (myelosuppression), nausea, and fatigue. In rare cases, allergic reactions or radiation-related complications may occur. Regular monitoring of blood counts is essential to prevent hematologic complications.
Samarium lexidronam pentasodium is an effective therapeutic option for managing bone pain in patients with metastases, providing significant symptom relief.